In addition, SMAD4-deficient HPV-positive cells have increased sensitivity to cisplatin treatment....Moreover, we found that SMAD4 silencing in HPV-positive HNC cell lines increases sensitivity to cisplatin treatment, suggesting that HPV-positive HNC with low SMAD4 expression may be preferentially susceptible to similar treatments.